바이오스펙테이터

Topic 1：Development of an exciting new radioimmunotherapy for cancer patients

Speaker 1: Dr. Brad Walsh, Chief Executive Officer, GlyTherix Ltd

Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential.

Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically. However, a  key challenge in RIT is the manufacture of the antibody to obtain a high yield stable product that can be distributed to treatment centers. Using the patented anti-GPC-1 Miltuximab® as a case study for new cancer treatment, we have illustrated a pathway:

** to achieve manufacture of the molecules suitable to treat large pools of patients

** for preclinical to clinical translation

Topic 2：IND-enabling CMC Strategies for mAb and bsAb: Faster and Better

Speaker 2: Rubin Jiang, Director of Antibody Process Development & MSAT, GenScript ProBio

In this talk, you will learn:

** Proprietary fast CMC platform guaranteeing the delivery of monoclonal antibody with high titer.

** The fast CMC turnaround from DNA synthesis to tox batch has been shortened to 6 months.

** Optimizing bispecific antibody CMC strategies, by combining cell line development, upstream cell culture process development, downstream purification process development and analytical method development, it is faster and better to produce bispecific antibodies in multiple formats.